11. Myasthenia gravis Clinical trials / Disease details

Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127

diseases per page:

Showing 1 to 10 of 332 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05681715 (ClinicalTrials.gov)	March 9, 2023	4/1/2023	A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study P ...	An Open-label, Crossover Study to Evaluate Rozanolixizumab Self-administration by Study Participants ...	Generalized Myasthenia Gravis	Drug: Rozanolixizumab	UCB Biopharma SRL	NULL	Not yet recruiting	18 Years	N/A	All	30	Phase 3	NULL
2	NCT05644561 (ClinicalTrials.gov)	January 2, 2023	1/12/2022	Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizuma ...	A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynam ...	Generalized Myasthenia Gravis;gMG	Drug: Ravulizumab	Alexion Pharmaceuticals	NULL	Not yet recruiting	6 Years	18 Years	All	12	Phase 3	NULL
3	NCT05451212 (ClinicalTrials.gov)	November 23, 2022	30/6/2022	Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia ...	A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase C ...	MuSK Myasthenia Gravis	Biological: MuSK-CAART	Cabaletta Bio	NULL	Recruiting	18 Years	N/A	All	24	Phase 1	United States
4	NCT05514873 (ClinicalTrials.gov)	October 31, 2022	22/8/2022	An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in ...	A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Effi ...	Generalized Myasthenia Gravis	Drug: zilucoplan (RA101495)	UCB Biopharma SRL	NULL	Recruiting	18 Years	85 Years	All	20	Phase 3	United States
5	JPRN-jRCT2031220102	28/10/2022	31/05/2022	A Study of Nipocalimab in Children Aged 2 to less than 18 Years with Generalized Myasthenia Gravis	An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Saf ...	Myasthenia Gravis	Nipocalimabwill be administered as an IV infusion. Participants aged 2 to less than [<] 18 years of a ...	Nakano Masayoshi	NULL	Pending	>= 2age old	<= 17age old	Both	12	Phase 2	Canada;Netherlands;nitedStates of America;Japan
6	EUCTR2021-002460-46-AT (EUCTR)	16/09/2022	23/05/2022	Evaluating Long-term Safety of Efgartigimod Administered Intravenously in Children With Generalized ...	A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX113-2006 to Evaluate Safety ...	Generalized Myasthenia Gravis MedDRA version: 21.1;Level: PT;Classification code 10028417;Term: Myas ...	Product Name: efgartigimod Product Code: argx-113 INN or Proposed INN: EFGARTIGIMOD ALFA	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12	Phase 2;Phase 3	France;United States;Canada;Belgium;Spain;Poland;Austria;Georgia;Germany;Netherlands;United Kingdom; ...
7	NCT05374590 (ClinicalTrials.gov)	August 18, 2022	1/4/2022	Evaluating Long-term Safety of Efgartigimod Administered Intravenously in Children With Generalized ...	A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safet ...	Generalized Myasthenia Gravis	Biological: Efgartigimod IV	argenx	NULL	Recruiting	2 Years	18 Years	All	12	Phase 2/Phase 3	Netherlands;Poland
8	NCT05390840 (ClinicalTrials.gov)	August 2022	20/5/2022	A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops ...	A Phase II Trial to Evaluate the Efficacy and Safety of Topical Ocular MG-O-1002 in Patients With Ne ...	Age-Related Macular Degeneration	Drug: MG-O-1002;Other: Placebo	Theratocular Biotek Co.	NULL	Not yet recruiting	45 Years	N/A	All	36	Phase 2	NULL
9	NCT05067348 (ClinicalTrials.gov)	July 21, 2022	23/9/2021	Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis	A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Efficacy and Safe ...	Myasthenia Gravis, Generalized	Drug: Tocilizumab Injectable Product	Tang-Du Hospital	NULL	Recruiting	18 Years	80 Years	All	64	Phase 2	China
10	NCT05265273 (ClinicalTrials.gov)	July 20, 2022	22/2/2022	A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis	An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Saf ...	Myasthenia Gravis	Drug: Nipocalimab	Janssen Research & Development, LLC	NULL	Recruiting	2 Years	17 Years	All	12	Phase 2/Phase 3	United States;Canada;Japan;Netherlands;Poland

First Previous1 2 3 4 5…34Next Last